Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with Oxaliplatin vs Mitomycin C for Appendiceal Tumors
NCT01580410Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2009
- Primary completion
- Oct 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin in appendiceal cancer (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Difference in the Number of Grade 3 or 4 Hematologic Toxicities at 4 weeks. Started May 2009; status: completed.
02
Drugs
oxaliplatin
03
Conditions
appendiceal cancer
Beyond the preview
Go deeper on NCT01580410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01580410.